Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes
Clinical Medicine Reviews in Vascular Health · 2010
DOI: 10.4137/cmrvh.s1534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine Reviews in Vascular Health, 2010. Verfasst von Jochen Seufert.
Themen: Diabetes mellitus
Abstract (Originalsprache)
uniklinik-freiburg.de Background: Combination oral glucose-lowering drug therapy is often required to maintain glycemic control in patients with type 2 diabetes. Single-tablet fixed-dose combinations of oral glucose-lowering agents provide one means to increase adherence, which may improve metabolic and clinical outcomes. A new fixed-dose combination of pioglitazone and extended-release metformin has recently been approved in the US in dosage strengths of 15 mg/1000 mg and 30 mg/1000 mg.
Aims
To review the clinical pharmacokinetics, efficacy and safety of the fixed-dose combination of pioglitazone and extended-release metformin, and to discuss the rationale behind its development. Data Sources: English-language articles from PubMed (without date restriction) using key words pioglitazone, metformin, extended-release and fixed-dose combination. Additional sources included published conference abstracts and US prescribing information.
Results
The efficacy and safety/tolerability of pioglitazone and immediate-release metformin as dual therapy have been established in randomized controlled trials. This combination provides durable glycemic control over 2 years and is associated with a low risk of hypoglycemia. Individually, both drugs have evidence for macrovascular benefits. Potential drawbacks include weight gain and edema with pioglitazone and gastrointestinal disturbances with metformin. Published clinical data regarding the specific combination of pio-glitazone and extended-release metformin (either as fixed-dose combination or dual therapy) remain scarce. However, bioequivalence
Zitieren
APA
Seufert, J. (2010). Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes. Clinical Medicine Reviews in Vascular Health. https://doi.org/10.4137/cmrvh.s1534
Vancouver
Seufert J. Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes. Clinical Medicine Reviews in Vascular Health. 2010. doi:10.4137/cmrvh.s1534
BibTeX
@article{Seufert2010,
author = {Seufert, Jochen},
title = {Pioglitazone-Metformin Extended-Release Fixed-Dose Combination for the Treatment of Type 2 Diabetes},
journal = {Clinical Medicine Reviews in Vascular Health},
year = {2010},
doi = {10.4137/cmrvh.s1534}
}
EUVIMED